At the news
? BULLISHIMPACT 8/10 PRESS-RELEASE filed Mar 9, 2026 at 16:30 ET
The FDA has accepted Mineralys Therapeutics' New Drug Application (NDA) for lorundrostat, a treatment for adult hypertension, and set a PDUFA action date of December 22, 2026. While the Phase 2 Explore-OSA trial missed its primary endpoint of reducing apnea-hypopnea index in sleep apnea patients, it showed clinically meaningful blood pressure reduction and a favorable safety profile, supporting the drug's potential in resistant hypertension.
- FDA accepted NDA for lorundrostat with PDUFA date of December 22, 2026
- Lorundrostat demonstrated 6.2 mmHg placebo-adjusted systolic BP reduction in Explore-OSA trial (p < 0.0003)
- Primary endpoint (AHI reduction) in Explore-OSA trial was not met
- Drug showed favorable safety profile with no serum potassium excursions above 5.5 mmol/L
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access